Duktales Adenokarzinom des Pankreas – Entstehung, Diagnostik, Therapie

Timm Reißig; Jens Siveke

doi:10.1007/s00761-020-00813-7

Duktales Adenokarzinom des Pankreas – Entstehung, Diagnostik, Therapie

Translated title of the contribution: Pancreatic cancer—emergence, diagnosis, therapy

Timm Reißig, Jens Siveke

Research output: Contribution to journal › Article › peer-review

Abstract

Only 8–9% of patients with ductal adenocarcinoma of the pancreas (PDAC) still live 5 years after diagnosis. In 2030, PDAC is projected to be the second leading cause of cancer-related death. Key reasons are diagnosis in metastatic state, complex tumor biology, and exceptional therapy resistance. Computed tomography scan and confirmation by biopsy or surgery are essential for diagnosis. Combined chemotherapy first-line protocols like FOLFIRINOX (5-fluorouracil [5-FU], folinic acid, irinotecan, oxaliplatin) and gemcitabine/nanoparticle albumin-bound (nab)-paclitaxel and second-line protocols like nanoliposomal (nal)-irinotecan/5-FU have led to longer survival. An improved molecular understanding may enable precision medicine strategies in selected patients. This article gives a review on development, diagnosis and therapy of PDAC.

Translated title of the contribution	Pancreatic cancer—emergence, diagnosis, therapy
Original language	German
Pages (from-to)	977-985
Number of pages	9
Journal	Onkologe
Volume	26
Issue number	10
DOIs	https://doi.org/10.1007/s00761-020-00813-7
State	Published - 1 Oct 2020
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s00761-020-00813-7

Cite this

@article{a36034883f46492c8eac0d7e7eb3931f,

title = "Duktales Adenokarzinom des Pankreas – Entstehung, Diagnostik, Therapie",

abstract = "Only 8–9% of patients with ductal adenocarcinoma of the pancreas (PDAC) still live 5 years after diagnosis. In 2030, PDAC is projected to be the second leading cause of cancer-related death. Key reasons are diagnosis in metastatic state, complex tumor biology, and exceptional therapy resistance. Computed tomography scan and confirmation by biopsy or surgery are essential for diagnosis. Combined chemotherapy first-line protocols like FOLFIRINOX (5-fluorouracil [5-FU], folinic acid, irinotecan, oxaliplatin) and gemcitabine/nanoparticle albumin-bound (nab)-paclitaxel and second-line protocols like nanoliposomal (nal)-irinotecan/5-FU have led to longer survival. An improved molecular understanding may enable precision medicine strategies in selected patients. This article gives a review on development, diagnosis and therapy of PDAC.",

keywords = "Chemotherapy, adjuvant, Chemotherapy, combination, Molecular targeted therapy, Pancreatic neoplasms/etiology, Precision medicine",

author = "Timm Rei{\ss}ig and Jens Siveke",

note = "Publisher Copyright: {\textcopyright} 2020, Springer Medizin Verlag GmbH, ein Teil von Springer Nature.",

year = "2020",

month = oct,

day = "1",

doi = "10.1007/s00761-020-00813-7",

language = "Deutsch",

volume = "26",

pages = "977--985",

journal = "Onkologe",

issn = "0947-8965",

publisher = "Springer Verlag",

number = "10",

}

TY - JOUR

T1 - Duktales Adenokarzinom des Pankreas – Entstehung, Diagnostik, Therapie

AU - Reißig, Timm

AU - Siveke, Jens

PY - 2020/10/1

Y1 - 2020/10/1

N2 - Only 8–9% of patients with ductal adenocarcinoma of the pancreas (PDAC) still live 5 years after diagnosis. In 2030, PDAC is projected to be the second leading cause of cancer-related death. Key reasons are diagnosis in metastatic state, complex tumor biology, and exceptional therapy resistance. Computed tomography scan and confirmation by biopsy or surgery are essential for diagnosis. Combined chemotherapy first-line protocols like FOLFIRINOX (5-fluorouracil [5-FU], folinic acid, irinotecan, oxaliplatin) and gemcitabine/nanoparticle albumin-bound (nab)-paclitaxel and second-line protocols like nanoliposomal (nal)-irinotecan/5-FU have led to longer survival. An improved molecular understanding may enable precision medicine strategies in selected patients. This article gives a review on development, diagnosis and therapy of PDAC.

AB - Only 8–9% of patients with ductal adenocarcinoma of the pancreas (PDAC) still live 5 years after diagnosis. In 2030, PDAC is projected to be the second leading cause of cancer-related death. Key reasons are diagnosis in metastatic state, complex tumor biology, and exceptional therapy resistance. Computed tomography scan and confirmation by biopsy or surgery are essential for diagnosis. Combined chemotherapy first-line protocols like FOLFIRINOX (5-fluorouracil [5-FU], folinic acid, irinotecan, oxaliplatin) and gemcitabine/nanoparticle albumin-bound (nab)-paclitaxel and second-line protocols like nanoliposomal (nal)-irinotecan/5-FU have led to longer survival. An improved molecular understanding may enable precision medicine strategies in selected patients. This article gives a review on development, diagnosis and therapy of PDAC.

KW - Chemotherapy, adjuvant

KW - Chemotherapy, combination

KW - Molecular targeted therapy

KW - Pancreatic neoplasms/etiology

KW - Precision medicine

UR - http://www.scopus.com/inward/record.url?scp=85088935770&partnerID=8YFLogxK

U2 - 10.1007/s00761-020-00813-7

DO - 10.1007/s00761-020-00813-7

M3 - Artikel

AN - SCOPUS:85088935770

SN - 0947-8965

VL - 26

SP - 977

EP - 985

JO - Onkologe

JF - Onkologe

IS - 10

ER -

Duktales Adenokarzinom des Pankreas – Entstehung, Diagnostik, Therapie

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this